Literature DB >> 15536051

Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans.

Mohamad Firas Bassissi1, Michel Alvinerie, Anne Lespine.   

Abstract

We studied the in vitro distribution of macrocyclic lactones (MLs), lipophilic anthelmintic drugs, in the plasma of several animal species including humans. First, in vitro spiking of goat plasma was performed with ivermectin, moxidectin, abamectin, doramectin, or eprinomectin. In parallel, goats were treated with subcutaneous injection of ivermectin. Then, cow, sheep, rabbit, pig, and human plasma were spiked with moxidectin. Four fractions were separated using KBr density gradient ultracentrifugation: very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and lipoprotein-deficient fraction. Cholesterol was analyzed by enzymatic assay and MLs by high-performance liquid chromatography. An average of 96% of MLs was associated with lipoproteins. The five MLs studied distributed similarly into goat plasma fractions with a preferential association with HDL (80-90%). Ivermectin partitioning in goat plasma was similar after in vitro spiking and in vivo treatment. In species displaying various lipoprotein profiles, moxidectin was also mainly associated with HDL. However, in human plasma, moxidectin was associated with a lesser extent to HDL (70%) and more to LDL (22%) when compared to other animal species. A relation between the plasma cholesterol content and pharmacokinetics of the drug is suggested. Our finding will allow further exploration of intestinal lymphatic absorption and milk elimination of these compounds-mechanisms in which lipoproteins are involved. In addition, possible improvements of new drug delivery systems are suggested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536051     DOI: 10.1016/j.cca.2004.07.011

Source DB:  PubMed          Journal:  Comp Biochem Physiol C Toxicol Pharmacol        ISSN: 1532-0456            Impact factor:   3.228


  5 in total

1.  Influence of dyslipidemia on moxidectin distribution in plasma lipoproteins and on its pharmacokinetics.

Authors:  Mohamad Firas Bassissi; Michel Alvinerie; Pascal Guy Pierre Martin; Bertrand Perret; Anne Lespine
Journal:  Pharm Res       Date:  2006-09-15       Impact factor: 4.200

2.  Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration.

Authors:  Firas Bassissi; Anne Lespine; Michel Alvinerie
Journal:  Parasitol Res       Date:  2005-12-10       Impact factor: 2.289

3.  Isolation and determination of ivermectin in post-mortem and in vivo tissues of dung beetles using a continuous solid phase extraction method followed by LC-ESI+-MS/MS.

Authors:  Antonio J Ortiz; Vieyle Cortez; Abdelmonaim Azzouz; José R Verdú
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

4.  Electrochemical Detection of Ivermectin Used for the Treatment of COVID-19 with Glutardialdehyde-Modified Glassy Carbon Electrode.

Authors:  Berna Koçak; Yeliz İpek
Journal:  Electrocatalysis (N Y)       Date:  2022-01-05       Impact factor: 2.933

5.  Optimising systemic insecticide use to improve malaria control.

Authors:  Hannah R Meredith; Luis Furuya-Kanamori; Laith Yakob
Journal:  BMJ Glob Health       Date:  2019-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.